Lung cancer biomarker tests: the history and perspective in Japan

Biomarker testing is recognized as being indispensable for selecting patients with advanced lung cancer. EGFR mutation is the first biomarker for therapeutic selection of lung cancer patients since the identification of the correlation between EGFR TKI response and EGFR mutation status. The biomarke...

Descripción completa

Detalles Bibliográficos
Autores principales: Motoi, Noriko, Yatabe, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Review Article on Selected Highlights of the 2019 Pulmonary Pathology Society Biennial Meeting
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354153/
https://www.ncbi.nlm.nih.gov/pubmed/32676353
http://dx.doi.org/10.21037/tlcr.2020.03.09

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354153/
https://www.ncbi.nlm.nih.gov/pubmed/32676353
http://dx.doi.org/10.21037/tlcr.2020.03.09

Ejemplares similares